CEO and President of Lineagen.

Affymetrix’ GeneChip technology incorporated into Lineagen’s FirstStepDx genetic evaluation service Affymetrix, Inc. and Lineagen, Inc.D., CEO and President of Lineagen. We are really pleased to formalize a Powered by Affymetrix partnership with an innovative organization like Lineagen, stated Dara Grantham Wright, VP Global Strategic Marketing for Clinical Applications at Affymetrix. We are focused on bring our technologies closer to the clinic also to the patients who will benefit most from high quality genetic info.However, most survivorship programs are within their infancy and so are largely underfunded still. Cancer Research Consciousness month is a perfect opportunity for America to improve its commitment to supporting study in the treatment and treatment of AYA with cancers and these applications, Echtenkamp concluded.. Acasti receives conditional acceptance for listing of class A shares on TSX-Venture Neptune Technology & Bioressources Inc. Acasti has received conditional authorization from the Exchange for the listing of its Class A talk about on the TSX-Venture . Acasti’s administration expects to waive all circumstances with respect to the Listing ahead of March 21, 2011.